Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 17/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | VCP | P55072 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172846 | 0.93 | HPRT1 (0.70) | HPRT1CYP3A4 | |
| SCHEMBL4713142 | 0.93 | HPRT1 (0.70) | HPRT1CYP3A4 | |
| SCHEMBL4715034 | 0.93 | HPRT1 (0.70) | HPRT1CYP3A4 | |
| SCHEMBL17194157 | 0.92 | HPRT1 (0.64) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| Pyrophosphoric Acid SCHEMBL15053837 | 0.89 | HPRT1 (0.66) | HPRT1CYP3A4POLB | |
| Pyrophosphoric Acid SCHEMBL15054252 | 0.89 | HPRT1 (0.66) | HPRT1CYP3A4POLB | |
| Pyrophosphoric Acid SCHEMBL15054286 | 0.89 | HPRT1 (0.66) | HPRT1CYP3A4POLB | |
| SCHEMBL15078235 | 0.88 | CYP3A4 (0.53) | HPRT1CYP3A4 | |
| SCHEMBL97316 | 0.88 | HPRT1 (0.75) | HPRT1MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL15078152 | 0.87 | POLB (0.68) | HPRT1MEN1ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. | 2015-05-21 | — | — | US | disclosed |
| WO-2013095684-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | GERON CORPORATION (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130072458-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120058975-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-03-08 | — | — | US | disclosed |
| US-8008308-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-08-30 | — | — | US | disclosed |
| WO-2011011710-A1 | METHODS OF TREATING VIRAL INFECTIONS | CHIMERIX, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072458-A1 | Methods of Treating Viral Associated Diseases | HAVCR2, EIF2AK2, TSLP | HPRT1 411/4885MEN1 1968/4885ALDH1A1 1045/4885 |
| US-20120058975-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | HPRT1 130/4885MEN1 464/4885ALDH1A1 3840/4885 |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | HAVCR2, EIF2AK2, TSLP | HPRT1 411/4885MEN1 1968/4885ALDH1A1 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.